Esperion Therapeutics, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for ESPR, updated each market day.
ESPR AI Sentiment
AI predicts Esperion Therapeutics, Inc. stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Esperion Therapeutics, Inc.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
Sector
Exchange
Market Cap
$559,846,850
Cap Tier
Employees
294
Headquarters
ANN ARBOR, MI
Listed Since
June 26, 2013
Website
ESPR Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ESPR Volatility
Esperion Therapeutics, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
